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Summary Interventional paediatric and congenital cardiology is expanding at a rapid pace.
Validated techniques (such as aortic or pulmonary valve dilatations and occlusion of persistent
ductus arteriosus and atrial septal defects) are improving thanks to the use of smaller introduc-
ers and sheaths, low-proﬁle balloons and novel devices. Moreover, catheter-based interventions
have emerged as an attractive alternative to surgery in other ﬁelds: pulmonary valve replace-
ment, balloon and stent implantation for native and recurrent coarctation, and percutaneous
closure of ventricular septal defects. On the other hand, percutaneous interventions in the
paediatric population may be limited by patient size or the anatomy of the defect. Hybrid
approaches involving both cardiac interventionists and surgeons are being developed to over-
come these limitations. Based on a better understanding of cardiac development, fetal cardiac
interventions are being attempted in order to alter the history of severe obstructive lesions.
Finally, some interventional procedures still carry a low success rate—–for example, pulmonary
vein stenosis, even with the use of conventional stents. Biodegradable stents and devices are
being developed and may ﬁnd an application in this setting as well as in others. The purpose
of this review is to highlight the advances in paediatric interventional cardiology since the
beginning of the third millennium.
© 2009 Elsevier Masson SAS. All rights reserved.
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E-mail address: joaquim miro@ssss.gouv.qc.ca (J. Miró).
1875-2136/$ — see front matter © 2009 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.acvd.2009.04.006
570
MOTS CLÉS
Cardiopathies
congénitales ;
Cathétérisme
cardiaque
interventionnel ;
Nouvelles techniques
être utile dans ce contexte et dans d’autres situations. Le but de cette revue de la littérature
est de souligner les nouveautés en cathétérisme cardiaque pédiatrique depuis le début du iiie
millénaire.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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Rbbreviations
DO Amplatzer duct occlude
SD atrial septal defect
SO Amplatzer septal occlude
LHS hypoplastic left heart syndrome
VSD muscular ventricular septal defect
S ostium secundum
DA persistent ductus arteriosus
FO patent foramen ovale
mVSD perimembranous ventricular septal defect
VS pulmonary vein stenosis
VOT right ventricular outﬂow tract
ackground
he ﬁeld of paediatric and congenital interventional cardi-
logy is developing at a rapid pace. Many studies are being
ublished, some reporting long-term results for validated
echniques in large populations and others reporting initial
esults for novel techniques. The purpose of this review is
o highlight the advances in paediatric interventional car-
iology since the beginning of the third millennium. The
eview has been divided into thematic sections. To maxi-
ize clarity, each section follows the same pattern and is
ivided into three subheadings: state of the literature in
000; landmark studies since 2000 (summarizing the cur-
ent consensus on the theme); and recent advances (new
echnologies, new devices and indications). To minimize
anuscript length and focus on novelties, basic techniques
nd accepted indications for usual interventions will not
e discussed. The reader will ﬁnd such information in
he relevant chapters of interventional cardiology text-
ooks.
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iascular occlusion: PDA
tate of the literature in 2000
urgical closure of PDA has been performed for more than
0 years. PDA transcatheter closure was introduced in 1967
nd has become the treatment of choice for most PDAs,
fter the neonatal period. Coils are used to occlude small
DAs. Many devices designed to occlude large PDAs have
een developed but most are associated with major draw-
acks, including a high incidence of residual shunt and/or
mbolization, complex delivery systems and the need for a
arge delivery sheath. The ADO (AGA Medical Corporation,
N, USA) was introduced in 1998 and was adopted quickly
y most interventionists for the occlusion of moderate and
arge PDAs.
andmark study
n 2004, Pass et al. reported the immediate and short-term
esults of the multicentre USA Amplatzer PDA occlusion
evice trial [1]. Four hundred and thirty-nine patients with
oderate to large PDAs were treated at a median age of 1.8
ears (range: 0.2—70.7) and weight of 11 kg (4.5—164.5).
DO implantation was successful in 435 out of 439 patients.
he overall morbidity was 9.4% and no deaths occurred. The
edian follow-up was 12 months and the 1-year occlusion
ate was 99.7%.
ecent advancesS. Abadir et al.
Résumé La cardiologie interventionnelle pédiatrique et congénitale avance à grands pas.
Les techniques percutanées déjà validées (comme la dilatation valvulaire aortique ou pul-
monaire, la fermeture de canal artériel persistant ou de communication interauriculaire)
s’améliorent encore, de part l’utilisation d’introducteurs et de gaines plus petits, de ballonnets
plus minces et de nouvelles prothèses. Par ailleurs, les techniques percutanées commencent
à être considérées comme une alternative valable à la chirurgie dans de nombreux domaines :
le remplacement valvulaire pulmonaire, la dilatation et l’implantation de stent dans le traite-
ment de coarctations natives ou récurrentes, la fermeture de communication interventriculaire.
Toutefois, dans la population pédiatrique, ces techniques se heurtent aux limites de poids du
patient ainsi qu’à l’anatomie de la malformation. Les techniques hybrides, impliquant à la
fois les chirurgiens et cardiologues interventionnels, se développent dans le but d’y remédier.
Basé sur une meilleure compréhension du développement cardiaque, le cathétérisme cardiaque
fœtal tente de se développer dans le but de modiﬁer le cours naturel des lésions obstructives
sévères. Enﬁn, les résultats de certaines interventions percutanées restent insatisfaisants, par
exemple le traitement des sténoses veineuses pulmonaires, malgré l’utilisation de stents con-
ventionnels. Le développement de stents biodégradables et de nouvelles prothèses pourraitoncern has been raised regarding PDA closure using the
DO in infants with large symptomatic ducts because of
he risk of aortic and/or pulmonary obstruction [2—4]. An
ngled ADO was designed to avoid protrusion of the occluder
nto the descending aorta but yet was never marketed [5].
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Most, if not all, ﬁstula anatomies can be approached in thisAdvances in paediatric interventional cardiology since 2000
In February 2008, the ADO II received European CE mark
approval; this is also a self-expanding nitinol mesh device,
fabric-free, shaped into a cylindrical waist with articulated
retention discs on both ends, and can be delivered through
4—5 French catheters. Preliminary results presented by
DeGiovanni at the 2008 meeting of the Association for
European Paediatric Cardiology
showed that it can close almost any type of PDA anatomy
[6]. Although limited currently by the manufacturer to
patients weighing above 6 kg, further studies will be needed
to assess the safety and effectiveness of the ADO II in
younger patients. In patients weighing at least 4 kg, we feel
comfortable closing PDAs less than 5.5mm using coils (PDAs
less than 2.5mm) or the ADO II (PDAs above 2.5mm). In
larger patients (> 10 kg), we feel that any size and anatomy
of PDA can be addressed with coils, the ADO I or II, or a mVSD
device [7].
For patients with PDA and pulmonary hypertension, clo-
sure can be attempted if the pulmonary/systemic ﬂow ratio
is above 2/1 or if the PDA occlusion test shows a decrease
in pulmonary pressure [8]. Few studies have reported on
the use of the Nit-Occlud Device for the closure of small-to-
moderate PDAs [9].
Vascular occlusion: collaterals and ﬁstulas
State of the literature in 2000
Transcatheter embolization has become the treatment of
choice for aortopulmonary collaterals, pulmonary arteriove-
nous ﬁstulas, venous collaterals and coronary artery ﬁstulas,
replacing surgical intervention in most cases. Intravascular
coils and detachable balloons were used ﬁrst and proved
to be successful for interventional occlusions of small- or
medium-sized vessels. However, they are not ideal in larger
ﬁstulas because of the risk of embolization to the systemic
circulation. Other devices have also been used (Rashkind-
Cardioseal, ADO or Gianturco Grifka, Amplatzer mVSD and
atrial VSD occluders) but have major drawbacks, including
complex delivery systems and large delivery sheaths.Landmark studies since 2000
In 2001, Qureshi and Tynan reported their experience of
using mainly controlled-release coils [10]. Forty patients
underwent coronary artery ﬁstula percutaneous occlusion;
w
b
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n
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Figure 1. Percutaneous closure of an arteriovenous pulmonary ﬁstula571
he procedure was successful in 39 of 40 patients. One 4-
onth-old infant died 6 h postprocedure. Embolization of
he device (coil or detachable balloon) was the main compli-
ation and occurred in six patients. All coils were retrieved
uccessfully. At follow-up, complete occlusion of the ﬁstula
as noted in 37 out of 39 (97%) patients.
ecent advances
he Amplatzer vascular plug was developed to obviate
ost of the difﬁculties described previously. This nitinol,
abric-free device, currently in its third generation, is
vailable in sizes that range from 4—16mm, and can be
elivered through low-proﬁle sheaths or guiding catheters
4—7 French). In a multicentre study, Hill et al. reported
heir initial experience of using the Amplatzer vascular plug
ﬁrst generation) for embolization of peripheral vascular
alformations associated with congenital heart disease
11]. Eighty-nine devices were implanted to treat 84 vessels,
n a total of 52 patients. Only one implantation failed, due
o non-progression of the device along the sheath through
tight curve. Collateral vessels (45/89; 51%) and ﬁstulas
29/89; 33%) were the lesions occluded most frequently.
o deaths or signiﬁcant procedural complications occurred.
ne patient underwent surgical ligation of PDA type C
fter removal of a 14mm ﬁrst-generation plug implanted 5
eeks previously, because of signiﬁcant residual shunt. The
econd-generation plug has a multisegmented and multi-
ayered design of nitinol to allow more efﬁcient occlusion,
s well as extended rims to improve wall apposition and
educe the risk of device embolization. Fig. 1 shows its
mplantation to occlude a pulmonary arteriovenous ﬁstula.
he latest generation, with its lobe shape, is designed
peciﬁcally for paravalvular leaks.
In the particular setting of coronary ﬁstulas, our expe-
ience is to attempt percutaneous closure of all signiﬁcant
alformations (associated with a typical murmur, chamber
ilation or evidence of coronary ischaemia), when the
natomy allows placement of a device distal to the last
ide branch without compromising coronary blood ﬂow.ay. Nevertheless, because of reduction in blood ﬂow, side
ranches proximal to the device are at risk of thrombosis in
he long term. The signiﬁcance of such long-term thrombosis
eeds to be addressed individually and preventive measures
antiplatelets and/or anticoagulation) adjusted accordingly.
using the Amplatzer vascular plug II.
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alvular dilatation: aortic
tate of the literature in 2000
ortic valvuloplasty is an established procedure that is
egarded as a valid alternative to the surgical manage-
ent of congenital aortic valve stenosis in paediatric
atients. However, the choice of technique remains highly
nstitution-dependent. A consensus seems to emerge in
avour of percutaneous dilatation in patients aged less than
8 years with no valvular calciﬁcations and favourable valvu-
ar anatomy (speciﬁcally excluding true unicuspid valves).
andmark studies since 2000
n a neonatal series of 110 patients aged less than 1 month,
cCrindle et al. reported the results of surgical versus tran-
catheter balloon valvuloplasty in neonatal critical aortic
tenosis [12]. Early mortality was 11% and 18%, respec-
ively, with no signiﬁcant difference, even after adjustment
or differences in patient characteristics. Likewise, major
omplication rates were not signiﬁcantly different. Freedom
rom aortic reintervention was similar for both groups (91%,
8%, 58% and 48% at 1 month, 6 months, 1 year and 5 years,
espectively). The rate of signiﬁcant aortic regurgitation
as higher after balloon valvuloplasty than after surgery,
lthough not signiﬁcantly so. The same team reported in
nother study that the only independent predictor of time-
elated mortality was the presence of moderate or severe
eft ventricular endocardial ﬁbroelastosis [13]. In a series
f 188 patients including neonates and older children, Fratz
t al. reported 10-year rates of freedom from aortic valve
urgery after balloon aortic valvuloplasty of 59% in patients
ged less than 1 month and of 70% in those aged at least 1
onth [14]. Clearly, these studies have increased the pop-
larity of this technique, although the debate is far from
ettled within the surgical community.
ecent advances
ight ventricular pacing during balloon inﬂation has been
eported and widely accepted, in order to decrease left
entricular stroke volume and pressure, thus increasing bal-
oon stability during inﬂation [15]. Furthermore, thanks to
he use of small arterial introducers (3 French), along with
maller balloons such as the Tyshak-Mini balloon dilata-
ion catheter (B. Braun Medicals, Melsungen, Germany),
alloon aortic valvuloplasty can be performed safely and
fﬁciently in neonates, as reported in a series of 20 patients
ith a mean age of 26 days and a mean weight of 3.6 kg
16]. Mean transvalvular gradient decreased from 76 to
6mmHg, changes in aortic insufﬁciency were grade one or
ess in 19 out of 22 procedures, while no signiﬁcant vascular
omplications were reported.
alvular dilatation: pulmonarytate of the literature in 2000
ulmonary valvuloplasty is an effective and safe treat-
ent for pulmonary valve stenosis, and is considered as
P
n
s
m
pS. Abadir et al.
he treatment of choice for non-dysplastic valves. Clas-
ic balloon dilatation is often ineffective for dysplastic
alves. RVOT palliative dilatation in patients with tetralogy
f Fallot is advocated by many teams but remains contro-
ersial.
andmark studies since 2000
he Valvuloplasty and Angioplasty of Congenital Anomalies
egistry relates to 533 patients aged 1 day to 55 years
median: 3.7 years) [17]. After a median follow-up of 33
onths, freedom from reintervention was 84%. Predictors
f a suboptimal long-term outcome included a small annu-
ar size (characteristic of patients with dysplastic valves),
higher immediate residual gradient and a smaller bal-
oon/valve ratio than in those with typical pulmonary valve
tenosis. The optimal suggested balloon/valve ratio was
etween 1.2 and 1.4.
Balloon dilatation of RVOT in a symptomatic infant with
etralogy of Fallot has been reported as a palliative step
efore corrective surgery [18—20].
ecent advances
hereas the use of cutting balloons has been reported for
ranch pulmonary artery stenosis (see later section) there
re no reports on their use in pulmonary valvular stenosis.
n an unpublished case, our team has used a cutting bal-
oon (slightly smaller than the annulus diameter, followed
y a larger regular balloon) successfully in a case of dysplas-
ic pulmonary valve, after unsuccessful traditional balloon
ilatation.
Implantation of stent in RVOT is quite recent [21].
n this report, nine symptomatic children (mean age:
3 days, range: 3—119) with tetralogy of Fallot and
nsalvageable pulmonary valves underwent RVOT stent-
ng. Arterial oxygen saturation increased from a median
f 73 to 94% and the median Nakata index increased sig-
iﬁcantly from 56mm2/m2 (range: 21—77) to 150mm2/m2
range: 123—231) over a median time of 76 days (range:
2—267) (p = 0.008). There were no deaths and no pro-
edural severe complications. Two patients developed
igniﬁcant cyanosis due to progressive muscular narrow-
ng below the stent and underwent successful additional
VOT stent placement. After a median time of 125 days
range: 40—315), six out of nine patients underwent suc-
essful repair; three are still awaiting surgical correction.
urther publications are needed to validate these initial
esults and sort out indications for this promising pro-
edure in a multidisciplinary discussion with our surgical
olleagues.
alvular dilatation: mitral
tate of the literature in 2000ercutaneous mitral commissurotomy (using the Inoue tech-
ique) is the treatment of choice for postrheumatic mitral
tenosis, where fusion of commissure is a predominant
echanism, but the procedure remains controversial in
atients with congenital mitral stenosis.
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Landmark studies since 2000
McElhinney et al. from Boston have reported their expe-
rience of transcatheter and surgical (valvuloplasty and
replacement) therapy for severe congenital mitral steno-
sis in 108 infants and children with a median age of 18
months [22]. Balloon mitral valvuloplasty was the preferred
mode of treatment in most cases, especially in those with
typical congenital mitral stenosis (thickened leaﬂets, short
or absent chordae tendinae and two separate, but often
closely spaced, papillary muscles) and double oriﬁce mitral
valve. Surgery was favoured when mitral stenosis was due
to a supravalvular ring, or when signiﬁcant mitral regurgita-
tion or important associated anomalies requiring cardiotomy
were present. Overall survival was 77% at 5 years. After
percutaneous treatment, signiﬁcant mitral regurgitation
occurred in 28% of cases, and freedom from failure of biven-
tricular repair or mitral valve reintervention was 55% at 1
year compared with 69% after surgical valvuloplasty. How-
ever, these results reﬂect the experience of only one large
referral centre, and surgery is the usual approach in most
other institutions.
Balloon dilatation and stenting of vessels:
pulmonary arteries
State of the literature in 2000
Percutaneous intervention has become the treatment of
choice for stenotic pulmonary arteries, most frequently
after surgery. The inclusion of high pressure balloons
and stents in the interventionist’s armamentarium at the
beginning of the 1990s has improved results considerably.
However, placement of stents in growing patients inevitably
leads to restenosis and is used more cautiously. As most
stents can be redilatated, we feel comfortable implanting
them in patients who have reached two-thirds of their
anticipated adult size (which corresponds to an age of 6 or
7 years). In younger patients, this alternative is also reason-
able if further surgery is anticipated, or in unstable patients.
Landmark studies since 2000
McMahon et al. reported their series of 664 Palmaz stent
implantations in 338 patients with a mean age of 12.2 years
[23]. Right ventricular to aortic pressure ratio decreased
from 0.66 before stenting to 0.45 immediately after stent-
ing, and was 0.50 at a mean follow-up of 5.6 years. Five
deaths were reported, including one fulminant pulmonary
oedema and one massive haemoptysis. The rate of resteno-
sis was 2%. Patients with a diagnosis of isolated congenital
pulmonary artery stenosis had a less optimal outcome and a
higher complication rate.
Recent advancesCutting balloons have been used successfully in the set-
ting of small-vessel pulmonary artery stenoses resistant to
high pressure balloon angioplasty [24]. In this study, 12
patients diagnosed with tetralogy of Fallot and a total of
38 pulmonary vessels were treated with the cutting balloon
C
N
e
F
r573
echnique, alone or associated with high pressure balloon
ilatation and/or stent implantation. The procedural suc-
ess rate was 92% (> 50% diameter increase). The diameter
f these vessels increased from 1.3± 0.7 to 2.8± 0.9mm
p < 0.001). There were no deaths, but one case of uncon-
ned tear needing resuscitation was reported among a total
f seven major complications. Follow-up was not available
or all patients, and revealed a 50% rate of occlusion (three
ut of six vessels) at 6 months, predominantly in those ves-
els treated with stent implantation. Further technological
dvances, such as biodegradable stents, may further expand
he indications for pulmonary artery stent implantation to
ll age groups [25].
alloon dilatation and stenting of vessels:
oarctation
tate of the literature in 2000
lthough widely accepted in the treatment of recoarcta-
ion (because of the increased difﬁculty and morbidity of
epeated surgery), consensus still has not been reached
n balloon angioplasty of native coarctation, due to its
omehow higher rate of recurrent stenosis and aneurysm
ormation, and, ultimately, reintervention, compared with
urgery. It is an accepted alternative to surgery for chil-
ren (aged: 1—7 years) but remains highly controversial in
eonates and infants because of a very high incidence (> 50%
n most series) of recoarctation. For patients near adult
ize (aged: 7 years or above 35 kg), primary stenting is used
ncreasingly; these patients will usually need planned elec-
ive redilatation after complete growth.
andmark studies since 2000
multi-institutional study reported an immediate success
ate of 97.9% (563 out of 565 procedures) after stenting
ative and recurrent aortic coarctation in patients aged
bove 4 years, and an acute complication rate of 14.3%
81 out of 565), including two deaths, six aneurysms and
ine aortic dissections [26]. The risk of aortic dissection
fter implantation of bare stent is higher in cases of nearly
tretic coarctation or if coarctation is associated with a
ypoplastic aortic arch. The incidence of aneurysm forma-
ion has been found to increase with a larger percentage
ncrease in coarctation diameter poststent implantation, a
alloon/coarctation ratio above 3.5 and balloon predilata-
ion of the lesion.
ecent advances
everal series report the growing use of covered stents
nd balloon-in-balloon in the setting mentioned above,
ith an almost 100% immediate success rate and good
idterm results [27,28]. Covered stents can also isolate aor-
ic aneurysms [29] or bail out from acute rupture [30]. The
heatham platinum-covered stent (NuMED Inc, Hopkinton,
Y, USA), made of platinum—iridium alloy and covered with
xpandable polytetraﬂuoroethylene, is used most widely.
ig. 2 shows its implantation in an acquired atresia, after
adiofrequency perforation [31].
574 S. Abadir et al.
Figure 2. Recanalization of a complete coarctation with isthmus occlusion in a 16-year-old patient using radiofrequency and covered
stent implantation. A, B. Simultaneous angiograms after gaining femoral and brachial arterial accesses, in frontal and lateral planes. C.
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[erforation of the occluded segment using a 0.035 radiofrequency
sing a coronary balloon. E. Implantation of a Cheatham platinum
ngiogram.
The use of biodegradable metal stents for the treatment
f aortic recoarctation in a 3-week-old neonate has been
eported [32]. This balloon expandable stent consists of
n absorbable magnesium alloy and seems promising, along
ith other types of resorbable stents, for the treatment of
evere vascular stenoses in newborns and infants. Further
tudies are needed, however, to validate the indications and
ong-term results.
alloon dilatation and stenting of vessels:
ulmonary veins
tate of the literature in 2000
ongenital PVS is a relatively rare condition, usually with a
uarded prognosis. Neither surgery nor percutaneous inter-
ention (balloon dilatation or stenting) achieves freedom
rom reintervention or death at midterm follow-up. After
urgical repair, overall freedom from death or reoperation at
years is around 50% [33]. Balloon dilatation and/or stenting
re seldom associated with mid- or long-term success.
andmark studies since 2000
n 2006, Devaney et al. reported their experience of surgical
epair of PVS over almost 15 years [34]. Among 36 patients,
4 had congenital PVS, four of whom underwent intraoper-
tive stent placement. Only one out of four was reported
s being alive 10 years after the procedure. Among the 22
atients with acquired PVS after correction of total anoma-
ous pulmonary venous connection, 11 underwent sutureless
ericardial marsupialization. This technique was found to be
ssociated signiﬁcantly with better survival without resteno-
g
o
w
i
o(Powerwire, Baylis Medicals, Montreal, Canada). D. Predilatation
red stent crimped on a balloon-in-balloon. F. Final lateral aortic
is. Median follow-up was 30 months (1 month to 14 years)
nd 14 out of 36 (38.9%) patients died during follow-up.
nly small studies reporting percutaneous balloon dilata-
ion and/or stent placement for congenital PVS have been
eported. In a non-randomized study, Prieto et al. compared
he results of balloon angioplasty versus stent implantation
or the treatment of acquired PVS after pulmonary vein iso-
ation for atrial ﬁbrillation ablation in 44 patients [35]. A
otal of 80 pulmonary veins were affected, but interven-
ion was impossible in 12 occluded vessels; 55 of the 68
ulmonary veins treated initially were available for follow-
p. Balloon dilatation was performed in 39 out of 55 lesions
nd primary stenting in 16 out of 55 lesions; immediate suc-
ess (residual stenosis at most 30%) rates were 42% and 95%,
espectively (p = 0.001). There were no deaths. Three sig-
iﬁcant complications occurred: one transient neurological
vent and two tamponades requiring drainage. There were
4 additional lesions treated with stent implantation during
mean follow-up of 25 months. At 4 years, freedom from
estenosis was 20% and 40% after balloon dilatation and stent
mplantation, respectively, and reached 80% for implanted
tents at least 10mm.
ecent advances
urther catheter-based interventions have been attempted:
alloon dilatation using high pressure balloons [36] and cut-
ing balloons to treat native lesions [37] or in-stent stenosis
38]. Again, immediate improvement is usually seen angio-
raphically, but recurrent stenosis occurs in a large majority
f patients. There is still no reported experience to date
ith the use of sirolimus or paclitaxel drug-eluting stents
n this situation, although unreported cases may exist. In
ur institution, a covered stent has been implanted in
Advances in paediatric interventional cardiology since 2000 575
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PFigure 3. Recanalization of an occluded left superior pulmonary
with perfect angiographic and haemodynamic results (F). The left lo
a 26-year-old girl with congenital left upper and lower
pulmonary vein occlusion with venovenous collaterals (unre-
ported case; Fig. 3). The occluded left superior pulmonary
vein was reopened using a terumo guide, and a covered
stent (Jostent, Abbot Vascular, Abbott Park, IL, USA) was
then implanted. Although no residual gradient was present
at the end of the procedure, restenosis developed over the
next few years and redilatation was required.
PFO closure
State of the literature in 2000
PFO closure in patients with previous cerebral embolic
events remains controversial. When indicated, however,
percutaneous closure is replacing surgery progressively.
Landmark studies since 2000
Results of percutaneous PFO closure in a large cohort of 307
patients with previous thromboembolic events using three
well-established occlusion devices (PFO-STAR, Amplatzer
PFO occluder and CardioSEAL/STARFlex) were reported [39].
Implantation was successful in all patients. Three major
peri-interventional complications occurred: one dislodg-
ment and two transient ischaemic attacks. Complete closure
rates were 56%, 69%, 94% and 96% immediately after the
procedure, at 1 month, 1 year and 2 years of follow-up,
respectively. Freedom from recurrence for the combined
endpoint of transient ischaemic attack, stroke or peripheral
embolism was 99% at 6 months. There was a trend towards
a lower rate of complications and a higher percentage of
complete PFO closures using the Amplatzer PFO occluder.Recent advances
A host of new devices has been introduced [40]. The
BioSTAR (Organogenesis, Canton, MA, USA)—–a bioabsorbable
o
r
h
t
T(A, B, C) followed by the implantation of a covered stent (D, E),
ulmonary vein was completely occluded (C) and not recanalizable.
evice—–consists of an acellular porcine intestinal collagen
ayer matrix mounted on the STARFlex framework, and has
een used in a phase I clinical trial [41]. Other devices
nclude the Premere occluder (St Jude Medicals, Inc., Maple
rove, MN, USA), the Solysafe septal occluder (Swissimplant
G, Solothurn, Switzerland) and the Intrasept PFO occluder
CARDIA, Inc., Burnsville, MN, USA), which is a new version of
he PFO-STAR occluder. Relative advantages of each device
eed to be determined.
While some indications (recurrence of neurological
mbolic event and platypnea—orthodeoxia syndrome) have
een validated, others (migraine and initial neurologi-
al embolic event) are still controversial. The results
f the MIST I trial (a prospective, randomized, double-
lind study aiming to evaluate the effectiveness of PFO
ercutaneous closure, using the STARFlex device, in elim-
nating migraine headache) were published earlier this
ear [42]. No signiﬁcant difference was observed in the
rimary endpoint between implanted and sham groups.
any ongoing randomized trials (PC-trial, CLOSURE I and
ESPECT for cerebrovascular events and PREMIUM, PRIMA
nd MIST II for migraine headaches) aim to compare dif-
erent strategies (percutaneous versus medical treatment)
nd different devices (mainly the Amplatzer and STARFLex
evices), in order to clarify the optimal management of
FO.
SD closure
tate of the literature in 2000
ercutaneous closure of OS ASD has become the treatment
f choice, except for very large defects and/or insufﬁcient
ims, where surgery may still be preferred. Several devices
ave been used, including the CardioSEAL/STARFlex devices,
he Sideris buttoned device, the HELEX device and the ASO.
he ASO has become the most widely used because of its
576 S. Abadir et al.
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migure 4. Percutaneous closure of a large ASD using the balloon
nﬂation of balloon positioned in the left atrium, followed by deploy
efore and after release of the device. F. Final position of the ASO
igh closure rates, safety of use, ease of deployment and
ventual retrieval, and ability to close large defects.
andmark studies since 2000
rom January 1997 to May 2008, 359 mostly paediatric
atients (median weight: 18.7 kg [range: 5.2—135] and
edian height: 109.5 cm [range: 63—178]) underwent 360
S ASD closure attempts using the ASO device at our
nstitution (unreported results). Systematic transcatheter
losure has been performed since 2000 (N = 280), regard-
ess of size. Successful implantation was achieved in 358
ut of 360 (99.4%) cases, with no failure since 2000. Signif-
cant complications occurred in 27 out of 360 (7.5%) cases,
ncluding one respiratory arrest with successful resuscita-
ion, transient high-degree atrioventricular block in 16 cases
43], one aortic erosion and one catheter-related tampon-
de (treated by surgical repair and percutaneous drainage,
espectively, with neither requiring device excision), one
evice embolization (recaptured and repositioned) and one
erebral embolism (with full recovery). No procedure-
elated death or surgical excision of a device occurred.
edian ASD size was 12mm (range: 4—33) at transthoracic
chocardiography and 14mm (range: 2.5—33) at transoe-
ophageal echocardiography. Median implanted device size
as 19mm (range: 4—38). Complete occlusion was achieved
n 86.5% and 96% of all cases, at 24 h and at 1 year, respec-
ively. Indications for closure of a small ASD (< 10mm) were
ight-to-left shunt or poor left ventricle compliance and con-
equent low cardiac output state.ecent advances
ong-term follow-up is now available after implantation of
he ASO device, conﬁrming the initial excellent results. Yet
oncern has been raised regarding the occurrence of cardiac
S
T
thnique. A. Angiogram in the right superior pulmonary vein. B, C.
t of both the left and right disk of the ASO device. D, E. Angiograms
release.
rosion after OS ASD occlusion using the ASO device [44]. A
otal of 24 cardiac events were reported in a retrospective
tudy, and were conclusive for device-related cardiac per-
oration. About one-ﬁfth occurred before hospital discharge
nd were amenable to intervention. About two-thirds
ccurred after hospital discharge and were thought to be
evice-related cardiac perforation [44]. A recent review
uggested that device oversizing and deﬁcient anterosupe-
ior rim are risk factors for cardiac perforation [45], which
as led most implanters to modify their guidelines and tech-
ique. Erosions have also been reported with other devices
CardioSEAL-STARFlex, Sideris buttoned, Cardia, etc), but
heir true incidence is less well known. Interestingly, this
omplication has not been reported with the HELEX device.
New devices have been introduced: the Intrasept in 2003
nd more recently the Occlutech Figulla device (Occlutech
mbH., Jena, Germany). As with PFO closure, the relative
dvantages of each device need to be determined in com-
arative studies.
Closure of a large OS ASD can be challenging, even
hen using the ASO. Different deployment strategies are
escribed (use of specially-shaped sheaths [Hausdorf],
eployment of ASO in the left or right pulmonary vein, etc).
n our experience, the use of the balloon technique [46]
deployment of the device using the support of a spherical
alloon inﬂated across the defect) has always been success-
ul, even in cases where all other techniques failed (Fig. 4).
Hybrid procedures have been performed to close OS ASD
hrough a peratrial approach, especially in infants [47].
VSD occlusiontate of the literature in 2000
he surgical closure of an mVSD can be a challenge for
he surgeon. It also involves a signiﬁcant risk of mortality,
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Figure 5. Percutaneous closure of a mVSD in a 4.4 kg infant, using the Amplatzer mVSD occluder. A. Angiogram in the left ventricle in
an oblique projection, delineating the mVSD. Previously, the ventricular septal defect had been crossed in a retrograde fashion from the
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Sleft ventricle; an arteriovenous loop to the right internal jugular ve
trunk. B. A long sheath has been advanced to the left ventricle. C a
releasing the device, showing normal foaming through it. F. Angiogr
reoperation and ventricular dysfunction due to right or left
ventriculotomy [48]. Percutaneous closure was attempted
in the late 1980s using various devices designed for other
malformations, notably the Rashkind and Clamshell devices,
and since 1998, using the speciﬁc Amplatzer mVSD occluder.
This self-expandable device consists of two retention disks
linked via a central connecting waist, which is 7mm long.
Both retention disks are 5mm larger than the connecting
waist. Device size (4—18mm) is usually chosen equal to or
1—2mm greater than the size of the VSD. The device can be
deployed in very small patients, as demonstrated on Fig. 5.
Various approaches can be used, according to the anatomy
of the mVSD: femoral vein for anterior defects, jugular vein
for midmuscular and apical defects, trans-septal, retrograde
aortic or perventricular (hybrid procedure).
Landmark studies since 2000
Immediate and midterm results of mVSD closure using the
Amplatzer mVSD occluder have been reported by Holzer
et al. [49]. In this USA registry, closure was attempted
in 83 procedures involving 75 patients (mean age: 1.4
years, range: 0.1—54.1), with a successful implantation
rate of 86.7%. In ﬁve out of 75 patients, implantation
was performed through a perventricular approach. Ten
major complications occurred, including two deaths (car-
diac perforation and haemorrhagic shock). At 12 months,
complete closure (or any residual shunt less than 2mm)
was 100%. Results of the European registry concerning tran-
scatheter closure of congenital ventricular septal defects
were reported by Carminati et al. [50]. Of the 430 patients,
119 had mVSDs. The Amplatzer mVSD occluder was the
device used most frequently. One death was reported after
attempted closure of a residual VSD in a 6-year-old boy with
U
s
p
t
id been created after snaring the guide advanced in the pulmonary
. Deployment of the left and right disks. E. Final angiogram before
months later, showing no residual shunt.
orrected transposition of the great arteries and multiple
SDs.
ecent advances
ybrid procedures using a perventricular approach for the
mplantation of an Amplatzer mVSD occluder have been
eported, with encouraging results [51,52]. As discussed
ater, hybrid procedures have the advantage of avoid-
ng cardiopulmonary bypass, while overcoming vascular
ccess limitations and haemodynamic instability in small
atients.
The use of Nit-Occlud coils has been reported as an alter-
ative to the Amplatzer devices for closure of mVSDs and
mVSDs of small to moderate size (≤ 7mm). In 2006, results
f the international experience were presented by Lê TP at
he Pediatric Interventional Cardiac Symposium. Forty-ﬁve
atients underwent percutaneous closure of both pmVSDs
N = 36) and mVSDs (N = 9) at a mean age of 14.7 years. Mean
SD size was 4.5mm (range: 3—8). Successful implantation
as achieved in 41 out of 45 cases. Coil displacement neces-
itating surgical removal occurred in one case. Complete
cclusion rate at 6-month follow-up was 82%.
mVSD occlusion
tate of the literature in 2000ntil the beginning of this century, surgery was the gold
tandard for pmVSD closure. Percutaneous attempts to close
mVSDs with Rashkind and buttoned devices (non-speciﬁc
o pmVSD) were reported in the late 1990s, but with a high
ncidence of residual shunt and complications.
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andmark studies since 2000 and recent
dvances
he Amplatzer pmVSD occluder was introduced in 2002 as
he ﬁrst device designed speciﬁcally for pmVSD occlusion.
his self-expandable device is also made of nitinol wire
ith Dacron fabric incorporated. It consists of two ﬂat disks
inked via a central connecting waist that is 0.5mm long.
ts diameter corresponds to the size of the device (ranging
rom 4 to 18mm). The left disk is asymmetric with almost
o (0.5mm) superior (aortic) rim and a longer 5mm infe-
ior rim. The right disk is symmetrical and 4mm larger than
he waist. Contraindications to percutaneous closure are
xtension of the defect to the subpulmonary area (so-called
ubarterial defects) as well as greater than mild aortic pro-
apse and/or insufﬁciency.
Initial and midterm results have been reported by Holzer
t al. in an international registry involving 100 patients [53].
uccessful implantation of the Amplatzer pmVSD occluder
as achieved in 93 out of 100 patients. Median VSD size
y transthoracic echocardiogram was 7mm (range: 1.5—13)
hile median device size was 10mm (range: 4—16). No
rocedure-related deaths occurred. Complications were
eported in 29 out of 100 patients including two complete
trioventricular blocks requiring permanent pacemaker
mplantation and nine new or increased aortic insufﬁciency
none progressing or requiring surgery). At 6-month follow-
p, complete closure rate was 83.6%.
The major concern is the occurrence of complete
trioventricular block during the procedure, shortly after
r even several months later, and requiring pacemaker
mplantation (ranging from 2 to 5.7% in multicentre stud-
es [50,53,54]). Although no risk factor has been linked
tatistically to this complication in these studies, most
nvestigators agree that oversizing of the device, large
ize of defect, patient weight below 10 kg and extension
f the defect posteriorly (inlet septum) or inferiorly (high
uscular septum) are plausible associations, and have
odiﬁed their inclusion guidelines and technique accord-
ngly. No consensus exists regarding the management of
omplete atrioventricular block. In cases of perprocedural
omplete atrioventricular block, if the device has not been
eleased, the interventional cardiologist usually chooses to
etrieve it [54,55]. Medical treatment using corticosteroids
s advocated by most teams if complete atrioventricular
lock develops in the ﬁrst week(s), with a good recovery
ate [54—56]. However, cases appearing later are usually
rreversible. Obviously, this complication has cooled the
nitial enthusiasm for the procedure considerably, and might
rompt modiﬁcations of the device or its abandonment if
he incidence has not decreased signiﬁcantly in the next
ublished series. Interestingly, complete atrioventricular
lock has not been described with other devices for pmVSD
cclusion, most notably the Nit-Occlud.
The use of robotic-assisted surgery has been reported
idely since early 2000, in extracardiac specialties. Car-
iac surgeons have also reported its use in performing
otally endoscopic coronary artery bypass and mitral valve
epair [57—59]. Reports in paediatric patients are infre-
uent. Robotically-assisted perventricular closure of pmVSD
as been performed by Amin et al. in an animal study, using
b
d
v
pS. Abadir et al.
he Da Vinci Surgical System (Intuitive Surgicals, Sunnyvale,
A, USA) [57]. An Amplatzer pmVSD device was implanted
uccessfully in ﬁve out of seven Yucatan pigs, which have
naturally occurring pmVSD. Nevertheless, further inves-
igations and studies are needed before its application in
umans.
VOT obstruction and percutaneous
ulmonary valve implantation
tate of the literature in 2000
he lifespan of a bioprosthetic right ventricular to pul-
onary artery conduit is limited because of progressive
bstruction and regurgitation. Endovascular treatment using
alloon dilatation and bare stent implantation were increas-
ngly accepted to extend conduit lifespan and reduce the
umber of open heart surgeries.
andmark studies since 2000
he team from Boston Children’s Hospital has reported its
xperience of endovascular stenting of obstructed right
entricular to pulmonary artery conduits [60]. Over a 15-
ear period, deployment of bare stents was attempted in
42 obstructed conduits in 221 patients. There were no
eaths and only one failure of attempted stent placement
as reported. Acute complications requiring surgical stent
emoval occurred in ﬁve patients. Median freedom from
onduit replacement after stent placement was 2.7 years.
ecent advances
hile resolving the problem of conduit obstruction, bare
tent placement inescapably leads to creation or deteriora-
ion of pulmonary regurgitation. To overcome this problem,
onhoeffer et al. were the ﬁrst to report their experi-
nce of transcatheter pulmonary valve replacement using
biological valve harvested from a bovine jugular vein
Medtronic, Inc., Minneapolis, MN, USA) and mounted in
balloon expandable vascular Cheatham platinum stent
Numed, Inc., Hopkinton, NY, USA) [61]. This procedure is
llustrated and described on Fig. 6. Owing to valve availabil-
ty and size, as well as the need for a stiff structure to anchor
he stent, indications for this valved stent are limited to
atients with right ventricular to pulmonary artery conduits
f 16—22mm diameter or presented RVOT. Yet most indi-
ations of pulmonary valve replacement are encountered
n patients who have dilated RVOT secondary to transannu-
ar patch repair for tetralogy of Fallot. To overcome these
imitations, Boudjemline et al. have devised and reported
n animal studies different ways to reduce the size of the
VOT before implanting the valved stent, such as a hybrid
pproach with a surgical pulmonary artery banding primarily
62] or implantation of an intravascular stent reducer [63].
ther percutaneous pulmonary valves have been implanted
y different teams.
In a recent study, Lurz et al. reported the imme-
iate and long-term results of percutaneous pulmonary
alve replacement performed by a single operator in 155
atients since the introduction of the Melody valved stent
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Figure 6. Percutaneous pulmonary valve implantation. A. Before implantation, simultaneous balloon inﬂation in the RVOT and coronary
ary o
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bangiography are performed to document any potential risk of coron
valved stent advanced over an extrastiff guide wire, by inﬂating th
position of the stent, and showing trivial pulmonary regurgitation.
in 2000 [64]. Successful implantation was achieved in 150
out of 155 patients (ﬁve immediate explantations). Major
complications included device dislodgement and insta-
bility (N = 2), homograft rupture (N = 3), compression of
the left main coronary artery (N = 1) and compression of
the origin of the right pulmonary artery (N = 1). Freedom
from reoperation was 86% and 70% at 30 and 70months,
respectively.
Percutaneous aortic valve implantation
Percutaneous aortic valve implantation has been achieved
in high-risk (high EuroSCORE) patients with severe aortic
stenosis as an alternative to open heart surgery. Several
valves have been used, mainly the Cribier-Edwards valve
and the CoreValve [65]. This technique, which is used only
in compassionate indications, has provided haemodynamic
and clinical improvement for up to 2 years in patients with
severe symptomatic aortic stenosis [66]. The valves cur-
rently available are being evaluated in the setting of North
American and European trials. The extremely low mortality
rate of surgical management in standard-risk patients, and
its favourable long-term follow-up, forbids the use of this
technique in this population for now, thus excluding young
patients.
Hybrid approach
State of the literature in 2000
The use of complex transcatheter techniques in the man-
agement of congenital heart disease can be limited in small
patients due to the use of large sheaths and their manipu-
lation within the heart. Open-heart surgery can also lead
to signiﬁcant morbidity and mortality in this population,
speciﬁcally for interventions such as mVSD closure or stage
I Norwood palliation.
Landmark studies since 2000 and recent
advances
To overcome these limitations, interventional cardiologists
and surgeons have worked hand-in-hand to develop hybrid
procedures. These have been attempted in the past 8 years
p
e
t
t
bbstruction with the valved stent. B. Deployment of the preloaded
er and outer balloons. C. Final angiogram conﬁrming the correct
n different ﬁelds—–mainly VSD closure, HLHS management
nd perventricular valve implantation.
Hybrid VSD closure was attempted in animal studies in
he late 1990s and shortly afterwards in humans [51,67].
right perventricular puncture is performed through a
ini-sternotomy, without cardiopulmonary bypass, and a
uide is advanced through the VSD under transoesophageal
uidance. A delivery catheter is advanced over the wire
nd the device is then deployed as usual. Two of the largest
eries of mVSD or pmVSD hybrid closures, both using the
mplatzer device, included 13 and 11 patients, with a mean
ge of 1.3 and 14.6 years, a success rate of 92.3% and 100%,
nd a complication rate of 23% (3/13) and 0%, respectively
52,68].
Ideally, hybrid interventions for HLHS should take place
n a specially designed hybrid suite [69]. The surgeon bands
oth pulmonary arteries through a median sternotomy, while
he interventional cardiologist implants a stent in the arte-
ial duct through a purse string in the main pulmonary
rtery. In cases of restrictive atrial septal communication, an
trioseptostomy is performed and/or a stent is placed across
he septum. Although the hybrid approach reduces the ini-
ial mortality of the ﬁrst procedure, it leads predictably to
ncreased interstage mortality and a more complex second-
tage palliation (arch reconstruction, stent excision and
idirectional Glenn procedure). Over a 2-year period, Cal-
arone et al. compared the results of 18 hybrid procedures
ith those of 25 classic Norwood stage I interventions in
he treatment of mainly HLHS [70]. Although not assigned
andomly, no difference was found between the two groups
n terms of age and weight at the time of the procedure.
urvival rate at 1 year was around 70%, with no signiﬁ-
ant difference between the two groups. Similar conclusions
ere drawn by Pizarro et al. who compared both approaches
n 33 high-risk neonates with HLHS [71]. It can therefore
e argued that this procedure still needs to be reﬁned to
atch the surgical results in high-volume centres. However,
t already represents an interesting alternative in centres
ith suboptimal surgical outcomes.
Although sequential (or pseudohybrid) approaches have
een described (initial surgical banding, followed by
ercutaneous PDA stenting and ASD enlargement), with
ncouraging results [72], the true hybrid approach submits
he patient to only one procedure, under more stable condi-
ions. An exclusively percutaneous approach (with bilateral
anding devices) has also been described but leads to more
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omplications arising from the procedure itself and the less
recise control of the ﬁnal pulmonary ﬂow, and has now
een abandoned in favour of the hybrid procedure.
Experienced teams now prepare the intra-atrial anatomy
uring the extended second-stage surgery (by performing
patched anastomosis between the right pulmonary artery
nd the superior vena cava or a lateral fenestrated Fontan
unnel) to allow percutaneous completion of the pallia-
ion [73,74]. When indicated, the patch can be perforated
ercutaneously and a single-covered or multiple-covered
tent(s) can direct the inferior vena cava ﬂow to the pul-
onary circulation. Alternatively, an intra- or extra-atrial
unnel (with large fenestration) can also be constructed dur-
ng the extended second-stage palliation. A covered stent
an thus be used during the percutaneous completion, with
evice closure of the fenestration [75]. Such percutaneous
ontan operations, by avoiding mechanical ventilation and
ardiopulmonary bypass, permit a much smoother transi-
ion to complete cavopulmonary physiology, thus reducing
ortality, morbidity and hospital stay predictably.
The hybrid approach (left ventricular apical puncture
hrough thoracotomy) is also used increasingly for aortic
alve implantation to overcome the limitations of a percu-
aneous approach [76].
etal interventions
tate of the literature in 2000
etal cardiac interventions generate a great deal of interest
ut are still controversial. They are based on the hypothe-
is that early relief of intracardiac obstacles might improve
he development of the affected cardiac chambers. The
rst fetal dilatation of the aortic valve, through abdominal
aternal and thoracic fetal punctures, was accomplished in
991. A worldwide study of 12 cases, however, showed dis-
ouraging results, with a technical success rate of 58% and
nly one patient still alive at the time of publication [77].
andmark studies since 2000
woretzky et al. from Boston reported their fetal aor-
ic stenosis series [78,79]. Fetal aortic dilatation was
ttempted in 22 fetuses. Four died in utero (one termina-
ion, three dismisses). Among the 18 liveborns, 14 had a
uccessful procedure, but only three ended with biventric-
lar circulation. Overall, technical success was achieved
n 16 out of 22 (73%) patients, with a better chance of
uccess if maternal laparotomy was an option. Details of
ntervention are described elsewhere [78]. The same team
dentiﬁed physiological features predicting the progression
f midgestation fetal aortic stenosis to HLHS, aiming at
ptimizing patient selection for fetal intervention. While
vailability of fetal balloon valvuloplasty is limited and
esults still need to demonstrate superiority compared
ith neonatal surgery, it clearly holds the promise of
romoting in utero left ventricle growth and improving
unction. However, these possible beneﬁts have yet to be
learly demonstrated and ought to be weighed against the
eﬁnite risks of such interventions. Further series need to
e published before these procedures become mainstream.
[S. Abadir et al.
ecent advances
etal pulmonary valvuloplasty has seldom been reported
80]. Atrial septostomy has been attempted in fetuses with
LHS and an intact or restrictive atrial septum [81]. Techni-
al success was achieved in six out of seven fetuses but only
ne was liveborn.
Finally, the use of high-intensity focused ultrasound has
een reported and seems to be a promising tool for fetal
ardiac interventions [82]. Using frequencies of 500 kHz to
0MHz, high-intensity focused ultrasound causes focal tis-
ue lesions at adjustable depths without the need for direct
issue contact and without injuring intervening tissue. This
on-invasive technique has been used in urology, neuro-
urgery and oncology, as well as in some reported cases of
ardiac conduction tissue ablation. Its more immediate fetal
pplication would be atrial septostomy in cases of HLHS, and
ossibly aortic or pulmonary valve stenosis relief. However,
t is still in the experimental phase and in vivo human studies
re awaited.
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